WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998030555) TREATMENT FOR CANCER AND COMPOUNDS FOR USE THEREWITH
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/030555    International Application No.:    PCT/US1998/000400
Publication Date: 16.07.1998 International Filing Date: 12.01.1998
Chapter 2 Demand Filed:    17.07.1998    
IPC:
A61K 31/00 (2006.01), A61K 31/375 (2006.01), A61K 31/555 (2006.01), C07D 307/62 (2006.01), C07F 9/94 (2006.01)
Applicants: SAKALOSKY, George, P. [US/US]; (US)
Inventors: SAKALOSKY, George, P.; (US)
Agent: LEVITT, Kenneth, E.; Dorsey & Whitney LLP, Pillsbury Center South, 220 South Sixth Street, Minneapolis, MN 55402-1498 (US)
Priority Data:
60/035,101 14.01.1997 US
Title (EN) TREATMENT FOR CANCER AND COMPOUNDS FOR USE THEREWITH
(FR) TRAITEMENT DU CANCER ET COMPOSES UTILISES DANS CE TRAITEMENT
Abstract: front page image
(EN)A treatment for cancer and compounds for use therewith are provided. The compounds treat cancer by correcting a TATA box lesion in DNA that leads to the cancer's uncontrolled cell proliferation. The preferred compounds each contain strontium; iodine; ascorbic acid; and a diamagnetic ion, either bismuth, zinc, or potassium. These components orient the components, transport it to lesion, dissociate the aberrational bonds of the lesion, hydrogenate the dissociated TATA nucleotides at the lesion, and reconvert the lesion's chemical structure to that of normal DNA.
(FR)La présente invention concerne un traitement du cancer et des composés utilisés dans celui-ci. Ces composés traitent le cancer en corrigeant une lésion de la boîte TATA de l'ADN qui entraîne la prolifération cellulaire incontrôlée caractéristique du cancer. Les composés préférés comprennent chacun du strontium, de l'iode, de l'acide ascorbique, et un ion diamagnétique de bismuth, de zinc ou de potassium. Ces constituants orientent le composé, le transportent jusqu'à la lésion, dissocient les liaisons anormales de la lésion, hydrogènent les nucléotides TATA dissociés sur le site de la liaison, et transforment la structure chimique de la lésion en une structure chimique d'ADN normal.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)